- Home
- ATOS vs NKTX Comparison
ATOS vs NKTX Comparison
Compare ATOS & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- NKTX
- Stock Information
- Founded
- ATOS 2009
- NKTX 2015
- Country
- ATOS United States
- NKTX United States
- Employees
- ATOS N/A
- NKTX N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- NKTX Biotechnology: Pharmaceutical Preparations
- Sector
- ATOS Health Care
- NKTX Health Care
- Exchange
- ATOS Nasdaq
- NKTX Nasdaq
- Market Cap
- ATOS 107.2M
- NKTX 123.5M
- IPO Year
- ATOS 2012
- NKTX 2020
- Fundamental
- Price
- ATOS $0.94
- NKTX $1.80
- Analyst Decision
- ATOS Strong Buy
- NKTX Strong Buy
- Analyst Count
- ATOS 3
- NKTX 6
- Target Price
- ATOS $6.17
- NKTX $14.40
- AVG Volume (30 Days)
- ATOS 1.5M
- NKTX 434.5K
- Earning Date
- ATOS 08-11-2025
- NKTX 08-12-2025
- Dividend Yield
- ATOS N/A
- NKTX N/A
- EPS Growth
- ATOS N/A
- NKTX N/A
- EPS
- ATOS N/A
- NKTX N/A
- Revenue
- ATOS N/A
- NKTX N/A
- Revenue This Year
- ATOS N/A
- NKTX N/A
- Revenue Next Year
- ATOS N/A
- NKTX N/A
- P/E Ratio
- ATOS N/A
- NKTX N/A
- Revenue Growth
- ATOS N/A
- NKTX N/A
- 52 Week Low
- ATOS $0.55
- NKTX $1.31
- 52 Week High
- ATOS $1.66
- NKTX $8.23
- Technical
- Relative Strength Index (RSI)
- ATOS 58.44
- NKTX 51.45
- Support Level
- ATOS $0.81
- NKTX $1.68
- Resistance Level
- ATOS $0.88
- NKTX $1.84
- Average True Range (ATR)
- ATOS 0.05
- NKTX 0.08
- MACD
- ATOS 0.01
- NKTX 0.01
- Stochastic Oscillator
- ATOS 84.07
- NKTX 80.95
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.